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KPT-9274 Decreases Colony Formation in AML 
Leukemic Patient Cell Lines  
• Acute Myeloid Leukemia (AML) is a cancer characterized by abnormal cell 
growth of immature myeloid cells. 
• It is believed that most patients have multiple malignant clones of 
leukemic stem cells, each differing in their responses to treatment. 
• NAMPT is a rate-limiting mechanism that produces nicotinamide adenine 
dinucleotide (NAD), a key metabolite essential for sustaining cellular 
energy metabolism. 
• NAD is an important cofactor and serves as a metabolite required for a 
number of cellular processes such as mitochondrial function, genomic 
stability, DNA repair, calcium homeostasis and gene expression. 
• NAMPT is over-expressed in various types of cancerous cells. They are 
reliant on the NAMPT salvage pathway for NAD production and do not 
efficiently utilize other pathways to produce NAD.
• Suppression of NAD production by inhibiting the NAMPT leads to loss of 
ATP, resulting in cell death without potentially toxic effects on non-
cancerous cells.
• NAMPT inhibition has potential to become an alternative treatment of AML 
by eradicating leukemic stem cells and malignant subclones.
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KPT-9274 Decreases Colony Formation in AML 
Leukemic Patient Cell Lines  
• Previous studies have displayed anti-tumor effects of NAMPT 
inhibitors in tumor models in vitro and in vivo.
• The purpose of this study is to evaluate the ability of KPT-9274, a 
novel, potent and selective NAMPT small molecule inhibitor to 
decrease colony formation in AML patient samples.
• In addition, self-renewal capacity is being evaluated in AML patient 
samples by assessing the ability of KPT-9274 to eradicate leukemic 
stem cell colonies.
• Six AML leukemic patient cells were 
diluted down to a specific number of 
cells (1,000-10,000 cells/plate) then 
treated with KPT-9274 or the vehicle 
control (DMSO). 
• Cells were plated and incubated on a 6-
well cell culture plate, along with a 
control group in a semi-solid medium.
• After two weeks, leukemic cell colonies 
were counted using an inverted light 
microscope. 
• The cells were washed with 20% RPMI 
media, underwent a dilution process to 
achieve a desired amount of cells, then 
re-plated to assess self-renewal 
capacity.
Conclusion
• Inhibition of NAMPT by KPT-9274 resulted in an overall decrease in 
acute myeloid leukemic colonies by 39.7 to 75.9 percent.
• NAMPT inhibitors have anti-leukemic properties and have potential to 
be an alternative treatment for AML. 
• Future considerations include assessing the self-renewal capacity of 
the AML patient cell lines. Regrowth of cells would indicate a 
resistance to the NAMPT inhibitor as a result of clonal mutations 
within the cell.
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Figure 4. Treatment of AML patient cell lines with KPT-9274 shows an overall decrease in
cell colonies relative to the vehicle.
KPT Vehicle KPT Vehicle KPT Vehicle KPT Vehicle KPT Vehicle KPT Vehicle
Rep 1 18 18 24 29 17 33 39 141 5 21 34 53
Rep 2 4 22 8 19 21 34 39 153 10 22 20 44
Rep 3 8 10 9 20 12 20 25 134 8 17 24 44
Pt 0096 Pt 0597 Pt 1177 Pt 1069 Pt 1361 Pt 1363
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Figure 1. Schematic of NAMPT inhibition
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Figure 2. Experimental design
Figure 3. A) Patient colony counts after 2 weeks; B) Colony formation assay in patient 1361 after 
treatment with KPT-9274 and re-plating (day 26); C) Patient mutational status and cytogenetics.
Leukemic colony
A)
B) C) Mutational Status Cytogenetics
Patient 1361
IDH1, NPM1, DNMT3a-
R882,NRAS NK*IDH1/2
Patient 0096 NMP1, TET2, NRAS, SRSF2
Insufficient 
Metaphases(46,XY[3])
Patient 0597 ASXL1, JAK2 Unknown
Patient 1177 NPM1, TET2, ASXL1 Unknown
Patient 1069
IDH2, DNMT3A-R882, SRSF2, 
FLT3-ITD Unknown
Patient 1363
NRAS, IDH1, NPM1, DNMT3a-
R882 NK
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